165 related articles for article (PubMed ID: 37115111)
1. Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: A multicenter retrospective review.
Learned C; Cohen SR; Cunningham K; Alsukait S; Santiago S; Lu J; Rothe M; Nichols A; Rosmarin D
J Am Acad Dermatol; 2023 Aug; 89(2):378-382. PubMed ID: 37115111
[No Abstract] [Full Text] [Related]
2. Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients.
Miller AC; Temiz LA; Adjei S; Duran MA; Sassmannshausen J; Dominguez A; Thomas C; Schmidt JD; Bernhardt M; Doolittle-Amieva CJ; Moshiri AS; Thompson AJ; Pyoung Kim-Lim P; Mattia AV; Tyring SK
J Drugs Dermatol; 2024 Jun; 23(6):e144-e148. PubMed ID: 38834228
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
Klepper EM; Robinson HN
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
Front Immunol; 2020; 11():611549. PubMed ID: 33584689
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
Zhang Y; Xu Q; Chen L; Chen J; Zhang J; Zou Y; Gong T; Ji C
Front Immunol; 2021; 12():738907. PubMed ID: 34721404
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients.
Moghadam P; Tancrede E; Bouaziz JD; Kallout J; Bedane C; Begon E; Bourgault-Villada I; Calugareanu A; Dereure O; Jendoubi F; Pham-Ledard A; Ingen-Housz-Oro S; Picard-Dahan C; Viguier M; Mahevas T; Jachiet M; Charvet E; Cassius C; Alexandre M; Lepelletier C
Br J Dermatol; 2023 Jul; 189(2):244-246. PubMed ID: 37155583
[No Abstract] [Full Text] [Related]
7. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study.
Huang D; Zhang Y; Yu Y; Jiang Y; Kong L; Ding Y; Shi Y; Gao Y
Int Immunopharmacol; 2023 Dec; 125(Pt A):111157. PubMed ID: 37925949
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report.
Pop SR; Strock D; Smith RJ
Dermatol Ther; 2022 Aug; 35(8):e15623. PubMed ID: 35669992
[No Abstract] [Full Text] [Related]
9. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.
Abdat R; Waldman RA; de Bedout V; Czernik A; Mcleod M; King B; Gordon S; Ahmed R; Nichols A; Rothe M; Rosmarin D
J Am Acad Dermatol; 2020 Jul; 83(1):46-52. PubMed ID: 32179082
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.
Yang J; Gao H; Zhang Z; Tang C; Chen Z; Wang L; Yang F; Chen S; He S; Liu S; Tang L; Xu Y; Hu Y; Ma L; Zhao Y; Luo X
Dermatol Ther; 2022 Aug; 35(8):e15648. PubMed ID: 35715972
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid.
Manzo Margiotta F; Fidanzi C; Bevilacqua M; Janowska A; Romanelli M; Manni E
Skin Res Technol; 2023 Oct; 29(10):e13488. PubMed ID: 37881049
[No Abstract] [Full Text] [Related]
12. Case report: Dupilumab for the treatment of bullous pemphigoid.
Wang M; Wang J; Shi B
Dermatol Ther; 2022 Jul; 35(7):e15541. PubMed ID: 35478478
[TBL] [Abstract][Full Text] [Related]
13. Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
Wang SH; Zuo YG
Front Immunol; 2021; 12():800609. PubMed ID: 34887875
[No Abstract] [Full Text] [Related]
14. Exacerbation of clinical manifestations of bullous pemphigoid after treatment with dupilumab.
Mariotti EB; Corrà A; Aimo C; Ruffo di Calabria V; Quintarelli L; Verdelli A; Caproni M
Clin Exp Dermatol; 2024 Mar; 49(4):399-400. PubMed ID: 38011325
[No Abstract] [Full Text] [Related]
15. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature.
Saleh M; Reedy M; Torok H; Weaver J
Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999579
[TBL] [Abstract][Full Text] [Related]
16. Hickam versus Ockham: atopic dermatitis and bullous pemphigoid or pemphigoid nodularis? Dupilumab solves the problem.
Mutton T; Bocchi C; Gaban A; Marzola E; Schettini N; Borghi A
Ital J Dermatol Venerol; 2024 Jun; 159(3):361-363. PubMed ID: 38695597
[No Abstract] [Full Text] [Related]
17. Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma.
Hansen I; Gebhardt C; Booken N; Schneider SW
J Dtsch Dermatol Ges; 2024 Apr; 22(4):587-589. PubMed ID: 38379256
[No Abstract] [Full Text] [Related]
18. Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review.
Liang J; Abulikemu K; Maolidan ; Hu F; Zhao J; Qiu Y; Wang Q; Sang Y; Hong Y; Kang X
Int Immunopharmacol; 2023 Mar; 116():109788. PubMed ID: 36731156
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab for bullous pemphigoid with intractable pruritus.
Seidman JS; Eichenfield DZ; Orme CM
Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045153
[TBL] [Abstract][Full Text] [Related]
20. Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
Russo R; Cozzani E; Gasparini G; Parodi A
Dermatol Ther; 2020 Jan; 33(1):e13190. PubMed ID: 31863534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
